Gynecologic Oncology | Specialty

The OncLive Gynecologic Oncology condition center page is a comprehensive resource for clinical news and expert insights on various types of gynecologic cancers, including ovarian cancer, endometrial cancer, and uterine cancer, among others. This section features news articles, interviews with gynecologic oncologists in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in gynecologic cancers.

Personalized Medicine Is Gaining Momentum in Advanced Endometrial Cancer

July 9th 2021

Molecular characterization of endometrial tumors has resulted in a boom of investigative efforts aimed at ushering in a new era of tailored therapeutic regimens for patients with these malignancies.

Research Reflections: O'Malley Relays Key Updates in Ovarian and Endometrial Cancers

July 5th 2021

Dr. O’Malley discusses key findings from 6 trials that were presented at the virtual 2021 SGO Annual Meeting on Women’s Cancer.

Adjuvant Advances Shine at ASCO 2021

July 1st 2021

Novel therapeutic strategies are poised to expand in adjuvant settings for patients with early-stage disease facing recurrence risks in the treatment paradigms for a range of tumor types after positive data from large phase 3 clinical trials were highlighted at the 2021 American Society of Clinical Oncology Annual Meeting

Coleman Centers the Discussion on Practice-Affirming ASCO Trials in Gynecologic Oncology

June 29th 2021

Practice-validating trials in cervical cancer, endometrial cancer, and ovarian cancer were the focus of the 2021 ASCO Annual Meeting in gynecologic oncology, each carrying relevant implications on extended therapy, surveillance, and biomarker testing.

Frontline Pembrolizumab Plus Chemo With or Without Bevacizumab Improves Survival in Cervical Cancer

June 22nd 2021

Pembrolizumab plus platinum-based chemotherapy with or without bevacizumab significantly improved overall survival and progression-free survival over the same platinum-based chemotherapy regimen with or without bevacizumab in patients with persistent, recurrent, or metastatic cervical cancer—irrespective of PD-L1 status.

FDA Grants Priority Review to Balstilimab for Recurrent or Metastatic Cervical Cancer

June 17th 2021

The FDA has granted priority review to the biologics license application for balstilimab for use in the treatment of patients with recurrent or metastatic cervical cancer who experienced disease progression on, or after, chemotherapy.

Trastuzumab Duocarmazine Shows Superiority Over Physician’s Choice for HER2+ Breast Cancer

June 8th 2021

The antibody-drug conjugate vic-trastuzumab duocarmazine was found to significantly improve progression-free survival over physician’s choice of treatment in patients with pretreated HER2-positive unresectable locally advanced or metastatic breast cancer, meeting the primary end point of the phase 3 TULIP trial.

Pertuzumab/Trastuzumab Combo Elicits Clinical Activity in ERBB2/ERBB3+ Uterine Cancer

June 7th 2021

The combination of pertuzumab and trastuzumab elicited a 37% disease control in patients with ERBB2/ERBB3-expressed, mutated, or -amplified uterine cancer.

Updates in Genitourinary, Gynecologic Cancers From ASCO 2021: Drs Nick Vogelzang and Erin Crane

June 7th 2021

OncLive sits down with Nicholas J. Vogelzang, MD, and Erin K. Crane, MD, MPH to discuss the biggest abstracts in genitourinary cancers and gynecologic cancers, respectively, at the 2021 ASCO Annual Meeting.

Prolonged Treatment With Bevacizumab Does Not Yield Further Survival Benefit in Ovarian Cancer

June 7th 2021

Although prolonged treatment with bevacizumab for up to 30 months is feasible with consistent safety data for patients with primary epithelial ovarian, fallopian tube, or peritoneal cancer, the regimen did not improve survival over the standard 15 month treatment regimen.

Niraparib Individualized Starting Dose Tolerable in Platinum-Sensitive Recurrent Ovarian Cancer

June 5th 2021

Niraparib, when delivered at an individualized starting dose, was found to be well tolerated in patients with platinum-sensitive recurrent ovarian cancer.

The Future of Endometrial Cancer Treatment

June 4th 2021

Experts give insight on what they are looking forward to in the endometrial cancer space.

A Look at Surgical Innovations in EC

June 4th 2021

Nicoletta Colombo, MD, PhD, reviews surgical advancements in endometrial cancer.

Novel Targets of Interest in EC

June 4th 2021

Experts in endometrial cancer comment on novel targets of interest that are currently being investigated.

PFS Improved With Niraparib Maintenance in BRCA+ Ovarian Cancer

June 4th 2021

Maintenance therapy with niraparib significantly improved progression-free survival in patients with BRCA-mutated ovarian cancer, according to results from three phase 3 trials.

Insight on Ongoing Trials in EC

June 4th 2021

Key opinion leaders take a look at the evolving treatment landscape in endometrial cancer, discussing ongoing trials in the space.

Incorporating Molecular Features into Choosing Adjuvant Therapy

June 4th 2021

Experts discuss the importance of incorporating molecular features into the selection of adjuvant treatment.

Therapeutic Sequencing in Endometrial Cancer

June 4th 2021

Experts in endometrial cancer comment on therapeutic sequencing in endometrial cancer.

Adjuvant Chemotherapy Fails to Improve PFS and OS in Locally Advanced Cervical Cancer

June 3rd 2021

The administration of adjuvant carboplatin and paclitaxel following standard cisplatin-based chemoradiation failed to demonstrate an improvement in progression-free survival or overall survival in women with locally advanced cervical cancer, according to findings from the phase 3 OUTBACK trial.

Managing AEs With Pembrolizumab and Lenvatinib

June 1st 2021

Key opinion leaders emphasize the importance of the management of adverse events in using pembrolizumab and lenvatinib.